ADPT Q3'26 Earnings: EPS estimate is (0.09) USD

What happened

Adaptive Biotechnologies is scheduled to report its fiscal third-quarter 2026 results on November 4, after the market closes, with disclosure expected at 4:00 p.m. Eastern Time. Revenue is estimated at 71.57 million USD, and earnings per share are expected to show a loss.

Confirmed

Global impact / market context

The report will show whether revenue and the loss per share differ from estimates. Revenue above expectations could indicate stronger sales, while a larger loss could point to higher costs or weaker profit per sale; the figures may influence investor expectations for the company’s financial progress.

Analyst inference

Past reported results in the supplied table show revenue varying across quarters, while earnings per share shifted from a profit to losses. Comparing the upcoming report with its estimates may help investors judge whether sales and earnings are improving or weakening.

Analyst inference

What to watch

1. Check the November 4 release for reported revenue against the stated estimate; the difference will show whether sales exceeded or fell short of expectations. Confirmed
2. Compare reported earnings per share with the expected loss; a larger loss could indicate that costs are weighing more heavily on financial results than anticipated. Analyst inference
3. Look for company commentary explaining revenue and costs alongside the results, because management's explanations may clarify whether any gap from estimates reflects lasting business changes. Analyst inference

Evidence

• Original source link unavailable